According to the most recent financial data from September 2026, the current EPS (TTM) is $5.15. Protagonist Therapeutics's EPS for 2025 came in at -$2.05, marking a decrease from $4.47 in 2024. For the quarterly period ending on Sep 30, 2026, PTGX's EPS was $3.32.
Protagonist Therapeutics had an annual EPS of -$2.05, marking a decrease of 145.9% from $4.47 in 2024. The quarterly EPS for the period ending Sep 30, 2026, was $3.32, marking a 635.5% increase from the same quarter last year. PTGX's TTM EPS stands at $5.15 as of September 2026. Protagonist Therapeutics's EPS for 2024 stood at $4.47, a 421.6% increase from 2023.
Protagonist Therapeutics has recorded an increase in EPS of 635.5% over the last 12 months (YoY, quarterly).
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| ORMP Oramed Pharmaceuticals Inc | 1.1 | 418.8% | N/A | N/A |
| OMER Omeros Corp | 7.29 | 98.1% | N/A | N/A |
| PTGX Protagonist Therapeutics Inc | 24.21 | -145.9% | N/A | N/A |
| OLMA Olema Pharmaceuticals Inc | N/A | 15% | N/A | N/A |
| VIVS VivoSim Labs Inc. | N/A | -214.7% | N/A | N/A |
| ORIC Oric Pharmaceuticals Inc | N/A | 19.7% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.